Albuminuria and CKD: Tackling the silent marker with SGLT2 inhibitors
165 views
Streamed on 20 Mar, 2025, 11:00 AM
ABOUT THIS SESSION
Chronic kidney disease (CKD) is often a silent but progressive condition, with albuminuria serving as a key marker of kidney damage and cardiovascular risk. Recent advances in nephrology have highlighted the crucial role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in slowing CKD progression and reducing albuminuria.